HB 1463 creates a new state framework for diabetes management centered on access, affordability, and referral to lower-cost care. It establishes a Task Force on Diabetes Management within the Department of Health to study whether the State Surgeon General should implement a referral program that directs people diagnosed with diabetes to federally qualified health centers and other covered entities, regardless of insurance status. The task force must report its findings and any referral criteria to the Governor and Legislature, and it expires after submitting its report unless reestablished by the Surgeon General.
If the task force recommends the program, the bill requires the State Surgeon General to establish it by January 1, 2027, unless the state instead seeks a federal Medicaid Section 1115 waiver or the Department of Health reports that federal law prevents implementation. The Department of Health would also have to create and maintain a website to collect patient information, identify appropriate clinics, and share referral information, and the referred health centers would have to make a good-faith effort to schedule appointments within 30 days. The bill also expands pharmacist authority to provide emergency supplies of insulin, glucagon, diabetes devices, and diabetic ketoacidosis devices when a patient is at risk of harm from running out.
The bill further changes insurance coverage rules for diabetes care. It requires health insurance policies and health maintenance contracts to cover laboratory and diagnostic diabetes screening, including hemoglobin A1c testing and retinopathy screening, if such services are otherwise covered. It caps patient cost-sharing at $35 for a 30-day supply of insulin, noninsulin, or glucagon drugs, and at $100 for a 30-day supply of medically necessary diabetes and diabetic ketoacidosis devices, for policies and contracts issued, renewed, or amended on or after January 1, 2026. It also requires pharmacies and other dispensers to report insulin drugs, glucagon drugs, diabetes devices, and diabetic ketoacidosis devices to the state prescription drug monitoring system.
The bill’s impact on state law is broad: it adds a new public health task force and potential referral program, amends emergency refill authority for pharmacists, imposes new insurance coverage mandates and cost-sharing limits, and expands reporting obligations under the prescription drug monitoring program. Affected parties include the Department of Health, the State Surgeon General, pharmacists, federally qualified health centers, insurers, health maintenance organizations, and people with diabetes who may benefit from lower-cost access to medication, devices, and screening.
Because there are no committee transcripts or recorded votes in the provided context, there is no documented legislative debate or vote history to gauge sentiment. Based on the bill text alone, the overall tone appears supportive of diabetes access and affordability, with an emphasis on reducing barriers to care. The main points of potential contention are likely to involve the insurance cost-sharing caps, the new reporting and website requirements, the scope of pharmacist emergency dispensing authority, and whether the referral program should be implemented directly by the state or through a federal Medicaid waiver.
HB 1463 would create new sections in Florida law governing diabetes management, insurance coverage, pharmacist emergency dispensing, and prescription monitoring. It would require the Department of Health to support a diabetes referral program if recommended, mandate coverage and limit cost-sharing for certain diabetes-related drugs, devices, and screenings in health insurance policies and HMOs, and require dispensers to report diabetes-related products to the prescription drug monitoring system. It also expands emergency refill authority for pharmacists and adds administrative duties for the Department of Health and federally qualified health centers.
No committee transcripts or votes were provided, so there is no recorded public debate to summarize. The bill’s structure and findings suggest a generally favorable, public-health-oriented approach aimed at improving access to diabetes treatment and reducing out-of-pocket costs. The absence of recorded opposition in the supplied materials means sentiment can only be inferred from the bill’s consumer-access focus, not from legislative discussion.
The most likely areas of contention are the insurance mandates and cost-sharing caps, which may be viewed by insurers as benefit expansions that could increase costs. Another possible issue is the bill’s administrative burden on the Department of Health, pharmacists, and health centers, including the creation of a referral website, patient data collection, and reporting obligations. There may also be disagreement over whether the state should implement the referral program directly or pursue a Medicaid Section 1115 waiver first, as well as privacy concerns related to collecting and sharing patient information.